Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.39 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 14/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18834254 | 0.91 | TRPC4 (0.40) | TRPC4TRPC5KCNH2TRPC1P2RX3 | |
| SCHEMBL18834945 | 0.90 | TRPC4 (0.39) | TRPC4TRPC5KCNH2TRPC1P2RX3 | |
| SCHEMBL18833918 | 0.89 | P2RX3 (0.35) | TRPC4TRPC5KCNH2TRPC1P2RX3 | |
| SCHEMBL18834366 | 0.88 | TRPC5 (0.38) | TRPC4TRPC5KCNH2TRPC1P2RX3 | |
| SCHEMBL20432022 | 0.88 | TRPC4 (0.42) | TRPC4TRPC5KCNH2TRPC1P2RX3 | |
| SCHEMBL19505572 | 0.88 | TRPC4 (0.47) | TRPC4TRPC5KCNH2TRPC1P2RX3 | |
| SCHEMBL18834916 | 0.87 | TRPC4 (0.45) | TRPC4TRPC5KCNH2TRPC1P2RX3 | |
| SCHEMBL21499678 | 0.86 | TRPC5 (0.48) | TRPC4TRPC5KCNH2TRPC1P2RX3 | |
| SCHEMBL19375436 | 0.86 | P2RX7 (0.35) | TRPC4TRPC5KCNH2TRPC1P2RX3 | |
| SCHEMBL21499680 | 0.85 | P2RX3 (0.39) | TRPC4TRPC5KCNH2TRPC1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969736-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | TRPC5, TRPC7, TRPC4 | TRPC4 3/4885TRPC5 1/4885KCNH2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.